Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has received marketing authorization from Japan's Ministry of Health,

1. Product Outlines

   1) Rabecure® Pack 400 and Pack 800 triple formulation packs for primary *Helicobacter pylori* eradication

    (1) Principal Agents (per blister sheet, equivalent to daily dose)

      Rabecure Pack 400

Pariet Tablets 10 mg (rabeprazole sodium)	2 tablets (1 tablet × 2 doses)
Sawacillin Tablets 250 (amoxicillin hydrate)	6 tablets (3 tablets × 2 doses)
Clarith Tablets 200 (clarithromycin)	2 tablets (1 tablet × 2 doses)

      Rabecure Pack 800

Pariet Tablets 10 mg (rabeprazole sodium)	2 tablets (1 tablet × 2 doses)

T t c6.25EMC   /P <Tw 37ard4 Tc 0 (nt)2 ndi]TJ (gTo.)4(c)-3((d)-13(o783(t)3.3s)-3( )][3nd2.50 t22T3.heTd ( )Tj   0.004

2. About Pariet®

    Pariet is a proton pump inhibitor (PPI) that was discovered and developed by Eisai. First launched in Japan in 1997, it is currently approved in more than 90 countries and territories worldwide. In Japan, Pariet is approved for multiple indications, including the treatment of gastric ulcers, duodenal ulcers and reflux esophagitis, and as an adjunctive therapy for use in *H.is*